The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Should AMTL be defined as a distinct diagnostic entity?
Jonathan Bond, MB BCh BAO, MRCPI, FRCPath, PhD, University College Dublin, Dublin, Ireland, discusses recent proposals to define acute myeloid/T-lymphoblastic leukemia (AMTL) as a distinct diagnostic entity. Prof. Bond reveals that the transcriptional overlap in interface acute leukemias provides support for the proposed classification of AMTL as a separate entity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
